CYR61 contributes to poor response to letrozole in ER positive breast carcinoma.

This study provides evidence that CYR61 maycontribute to poor response to letrozole treatment and targeting CYR61 may improve endocrine resistance in ER-positive breast cancer.
PMID: 27113745 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - April 25, 2016 Category: Cancer & Oncology Authors: Jia X, Liu G, Cheng J, Shen Z, Shao Z Tags: Curr Cancer Drug Targets Source Type: research